Jazz Pharmaceuticals plc

JAZZ · Nasdaq · ·

比較

$240.40-3.1%11月12日終値

2026年9月30日までの数値（2026年11月2日提出の10-Qより）

1W: +2.4%
1M: +14.7%
3M

Jazz Pharmaceuticals plc（JAZZ）株——良い事業でしょうか？ — InspectStocks

Jazz Pharmaceuticals plc

JAZZ · Nasdaq · ·

比較

$240.40-3.1%11月12日終値

2026年9月30日までの数値（2026年11月2日提出の10-Qより）

1W: +2.4%
1M: +14.7%
3M

Just reported

Q3 2026 results

From Jazz Pharmaceuticals's results release of 2026年11月2日; its quarterly report has since been filed.

Revenue
Actual
$1.24B
+10% y/y
+2.9% q/q
Guided
—
No guide given
EPS, GAAP
Actual
-$7.48
Guided
—
No guide given
Operating income, GAAP
Actual
-$413.4M
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$4.775B – $4.85B+13% y/y Raised +2.9%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Jazz Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

キュレーション
Biotech
InspectStocks 編集 · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
株価、1 年
+28.4%
売上、1 年
+12.9%
+13
A 8B 4C 5D 1F 1

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

どうやって稼いでいるか

Xywav for narcolepsy and idiopathic hypersomnia41%
Epidiolex for seizures associated with certain rare epilepsy conditions26%
Rylaze for patients with leukemia or lymphoma who cannot take a common asparaginase medicine10%
Zepzelca for small-cell lung cancer8%
Xyrem for narcolepsy4%

売上構成比は2025の推計であり、提出された報告書の数字ではありません。

競合

何を売っているか6

Xywav
A low-sodium liquid medicine for cataplexy and excessive daytime sleepiness in people with narcolepsy, and for idiopathic hypersomnia in adults.
Epidiolex
A purified cannabidiol liquid medicine used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
Ziihera
An antibody medicine for certain cancers with high levels of human epidermal growth factor receptor 2 (HER2), including bile duct cancer and, in the United States, stomach and related cancers.

さらに3件を表示

Modeyso
A medicine for diffuse midline glioma with an H3 K27M mutation that has progressed after earlier treatment; it is also approved for this condition in Japan.
Zepzelca
A cancer medicine used with atezolizumab as maintenance treatment for some adults with extensive-stage small-cell lung cancer.
Rylaze
An injectable medicine used as part of chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma when a patient is hypersensitive to an E. coli-derived medicine.

誰が買っているか5

Patients use Jazz's medicines under prescriptions from healthcare professionals.
ESSDS is the certified specialty pharmacy that receives U.S. Xywav and Xyrem and ships them directly to patients.
Onco360 is the certified specialty pharmacy that ships Modeyso directly to patients in the United States.

さらに2件を表示

Specialty pharmacies and distributors supply Epidiolex to patients and healthcare providers.
McKesson, Cencora and Cardinal distribute Zepzelca, Rylaze, Ziihera and other medicines to hospitals and healthcare customers.

何に支えられ、何に崩されうるか

事業が頼っているもの

1The business continues to depend substantially on Xywav sales and on maintaining physician and patient use and insurance coverage for it.
2Xywav and Xyrem require a restricted distribution system: prescriptions must go through a certified pharmacy under a Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy.
3Jazz relies on outside manufacturers and suppliers for many medicines. Patheon supplies several products, and the company identifies sole-source suppliers for products including Modeyso and Vyxeos.
4Sales depend on regulatory approvals, continued access to reimbursement from insurers and pharmacy benefit managers, and the results of required follow-up trials for some accelerated approvals.

うまくいかなくなる可能性

1Generic high-sodium oxybate medicines, branded alternatives and new sleep-disorder treatments may reduce demand for Xywav and Xyrem or lead insurers to offer less favorable coverage.
2Epidiolex sales depend on continued prescribing and insurance reimbursement; the medicine also faces competition from other seizure treatments and could face generic competition under patent-settlement terms or earlier in certain circumstances.
3Some cancer medicines have accelerated or conditional approvals that depend on follow-up trials; unsuccessful trials or regulatory action could restrict or remove an approval, as happened when the second-line small-cell lung cancer indication for Zepzelca was removed in September 2026.

財務諸表をすべて見る →

Jazz Pharmaceuticals plcについて

Jazz develops and sells prescription medicines, focusing on rare sleep disorders, epilepsy and cancers. Its largest products include Xywav for narcolepsy and idiopathic hypersomnia and Epidiolex for seizures linked to certain rare conditions. It also sells cancer medicines and runs clinical trials to test new medicines and uses for existing ones. At September 30, 2026, about 17,550 patients were taking Xywav (high confidence).

本社: Dublin, Ireland
設立: 2003
従業員数: 2,890 (December 31, 2025, high)
上場市場: Nasdaq
決算期: December 31

Jazz Pharmaceuticals plc 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。

Just reported